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Pediatric thyroid carcinoma is relatively uncommon. But variability in incidence rate by race, sex, age at onset/diagnosis, and geo-
graphic local had been observed in adult thyroid carcinoma in the USA. We aimed to examine the patterns, rates, and temporal
trends of thyroid carcinoma among pediatric patients (0–19 years) between 1973 and 2007. The Surveillance, Epidemiology, and
End Results (SEER) data of the National Cancer Institute were utilized. Data were available on sex, age at diagnosis, race/ethnicity,
and geographic locale (9 SEER registries) and were used for rates and trends computation. The frequency and percentage, percent
changes (PCs) were calculated by using 1 year of each endpoint. Similarly, the annual percent changes (APCs) were calculated as
well, with APCs estimated using weighted least square methods. Between 1973 and 2007, 1,360 thyroid cancer cases were ascer-
tained in the 9 SEER areas (n = 247,638,734) in the USA. The percent change was 47.9, while the APC was signiﬁcantly diﬀerent
from 0, 1.0 (95% CI: 0.5–1.6, P<0.0001). The rate ratio (RR) was signiﬁcantly lower in 1975 (RR: 0.62, 95% CI: 0.38–0.98,
P = 0.03) relative to the rate between 1973 and 2007 (RR: 1.60, per 100,000, 95% CI: 1.50–1.70), but higher in 2007 (RR: 2.3 per
100,000, 95% CI: 1.70–3.10; RR: 1.44, 95% CI: 1.05–1.93, P = 0.02). The rate was signiﬁcantly higher in whites relative to blacks,
highestamongagegroupof15–19yearsandgirls,andinsomeSEERregistries,withsomesigniﬁcantPCinConnecticut.Thistem-
poral trend study of pediatric thyroid carcinoma indicates increase in the rate of this malignancy given the percent change and the
annual percent change between 1973 and 2007. In addition, the incidence was higher among girls, lower among blacks, highest in
age group of 15–19 years, and relatively higher in SEER registries with predominantly white or Hispanic populations.
1.Introduction
Thyroidcarcinomasaretumorsthatoriginatefromepithelial
cells and are relatively rare. Whereas the follicular and pap-
illary, which are highly diﬀerentiated cells and anaplastic
(poorly diﬀerentiated) types, arise from follicular cells, med-
ullary cells types arise from parafollicular C cells, which are
cells associated with calcitonin production [1]. The progno-
sis for papillary and follicular carcinoma subtypes had been
reported to be good, while the anaplastic carcinoma is poor
in prognosis. The papillary and follicular cell types are the
most common, accounting for an estimated 80–90% of all
thyroid carcinomas. Relative to leukemia, CNS/brain tumor,
and lymphoma in children, thyroid cancer is rare, aﬀecting
approximately 1 in every 1000 to 2000 children in the United
States. Based on the Surveillance Epidemiology and End
Results (SEER) Cancer Registries, the age-standardized inci-
dence rates (1987–1991) were 2.5 per 100,000 for males and
6.4 per 100,000 for females [2]. Sex and racial variability
has been observed in SEER registries. The incidence from
the SEER (1983–87) was 1.0 in black males and 2.2 in white
males per 100,000, while the incidence was 2.7 for black fe-
males and 5.8 per 100,000 for white females [3]. Sex variabil-
ity as shown in nonmedullary diﬀerentiated cell types peaks
after puberty and increases to three-fold diﬀerences during
child-bearing years in women and declining thereafter.2 ISRN Oncology
In general, the incidence is two times as likely in whites
compared to blacks, with Asians, compared to white or
blacks, more likely to be diagnosed with thyroid cancer [4].
With respect to presentation, there is variability in tumor
subtypebysex,withfemale-to-maleratioof1:3forpapillary
and follicular cell types, but no such female-male ratio is
seeninmedullarycarcinoma,whichmaybeduetotheimpli-
cation of increased estrogen receptors in papillary and folli-
cular cell types [5].
Time trends in papillary and follicular thyroid cancer
indicated an increase until about 1980 [6]. Whereas, in the
USA, incidence increased between 1947 and 1978, rates
tended to plateau between 1978 and 1979 [7].
Like in most pediatric malignancy, the risk factors for
pediatricthyroidcancerarenotwellunderstood.Thismaybe
due to apparent restricted or limited epidemiologic interest
in this rare but relatively good prognosis and survival tu-
mor, as well as the several histopathological subtypes and
prognostic variability associated with the cell subtypes. Epi-
demiologic data strongly suggest ionizing radiation, which
may tend to increase the incidence in children, given exten-
sive use of radiation today in the treatment of other
childhood malignancies (leukemia, lymphoma, CNS/brain,
Wilms’ tumor, neuroblastoma, etc.). Inherited susceptibility
is seen an estimated 3% of thyroid cancer, with such presen-
tations suggested to be clinically more aggressive [8]. Ger-
mline mutations in the ret protooncogene, which is an auto-
somal dominant inheritance with high penetrance and vari-
able expression have been associated with an estimated 20%
of medullary thyroid cancer. Familial contributions to thy-
roid cancer had been observed in which the rate for the
oﬀspring of thyroid cancer patients increased by multiple-
folds [9]. Evidence is conﬂicting on speciﬁc gene alteration
implicated in thyroid cancer. However, growth factor recep-
tors, oncogenes (ras gene, ret protooncogene, and ret/ptc),
and tumor-suppressor genes (p53 point mutation) had been
associated with thyroid carcinogenesis [10, 11]. The implica-
tion of the growth factor in thyroid carcinogenesis is plau-
sible given that follicular cell growth is regulated by growth
factors while thyroid cell proliferation is essentially control-
led by thyroid-stimulating hormone.
Epidemiologic predisposing and protective factors not
established in thyroid carcinogenesis include smoking, diet
(high iodine level and increase risk, vegetables and decreased
risk), alcohol (increased risk), hormones (elevated TSH sec-
retion, puberty, pregnancy, and labor, oral contraceptive,
thyroidectomy, goitrogens, and radiation therapy), weight
(increasedBMIinwomenandincreasingrisk),ionizingradi-
ation(establishedriskfactor),withdosesaslowas0.1Sievert
associated with increased risk, and is dependent on the age at
exposure—more sensitive during early years [12], and dise-
ases and therapeutics (hyper- or hypothyroidism, thyroid
adenoma, goiter, thyroiditis, iodine deﬁciency/endemic goi-
ter, and breast cancer) [13]. These risk and possible predis-
posing factors remain inconclusive except ionizing radiation,
due probably to confounding eﬀects, such as the association
between breast cancer and thyroid carcinoma, diets, and
alcohol.
Epidemiologic risk factors in childhood or pediatric thy-
roid carcinoma have not been explored relative to the studies
in adults. However, hormones, somatic events, inherited sus-
ceptibility,andexposuretoionizingradiationarefactorsthat
are similarly implicated in pediatric thyroid carcinoma.
Additionally, data suggest ionizing radiation with increasing
predisposition to pediatric thyroid cancer. Children treated
with external X-irradiation and by external exposure to
active iodine for enlarged thymus glands were demonstrated
to develop papillary-follicular thyroid carcinoma after a
latency of an estimated ten years [14]. Epidemiologic data on
temporal incidence trends are needed on pediatric thyroid
carcinoma that will allow us to have comparable data as
in adult presentation with respect to sex variability, racial/
ethnic variance, geographic locale, and age at onset in the
United States.
Thepresentstudysoughttoexaminetheincidencetrends
(percent change and annual percent change) in pediatric
thyroid cancer (1973–2007) using the Surveillance Epidemi-
ology and End Results (SEER) dataset from the 9 SEER regis-




poral trend study to assess the incidence rate/trend in pedi-
atric thyroid cancer as well as to examine the incidence rate/
trendbyrace,sex,agegroupatdiagnosis,andSEERregistries
(geographic locale).
2.1. Study Population. The study population comprised chil-
dren of age 0–19 years with newly diagnosed thyroid cancer
between 1973 and 2007.
2.2. Variables. This study assessed the incidence rate/trend
in the overall pediatric population at risk and examined the
rate diﬀerences by sex, race, age at diagnosis, and SEER geo-
graphic areas. Sex was classiﬁed as male and female for boys
and girls, respectively. Race was classiﬁed as black, white,
andothers, whereothers comprised AmericanIndian-Alaska
native, Asia-Paciﬁc Islander, and others. The age at diag-
nosis was grouped into (a) 0–4 years, (b) 5–9 years, (c) 10–
14 years, and (d) 15–19 years. The SEER registries represent
geographic locale where the tumors were diagnosed along
with the pediatric population at risk. The SEER areas used
in this study were the seven initial registries, which began in
1973, plus Seattle and Atlanta Metropolitan registries, which
started in 1975.
2.3. Data Source. The National Cancer Institute (NCI), an
agency of the National Institute of Health (NIH), supports
theSurveillanceEpidemiologyandEndResults(SEER)prog-
ram. SEER collects data on all malignancies diagnosed and
conﬁrmed through histopathology (biopsy) in all SEER eli-
gible cancer registries. The initial registries comprised San
Francisco (SA), Connecticut (CN), Detroit Metropolitan
(DM), Hawaii (HI), Iowa (IO), New Mexico (NM), Seattle
(SE), Utah (UT), and Atlanta Metropolitan (AM). Of theseISRN Oncology 3
nine registries SE and AM joined SEER in 1975 implying
thatthyroidcancerincidencedatawerenotavailableforthese
two registries during 1973 and 1974. These 9 SEER registries
represent an estimated 11% of the US population.
SEER data had been validated and shown to be reliable
in population-based studies. SEER employs highly qualiﬁed
data processor and entry clerks which have resulted in the
high quality of the SEER data for research purposes. While
SEERremainsareliablesourceforcancerincidenceandmor-
tality, estimate of survival using these data remains ques-
tionable due to the lack of variables on treatment such as
chemotherapy as well as variable survival times.
2.4.StatisticalAnalysis. Weobtaineddataonthethyroidcan-
cer counts as well as the pediatric population at risk in the
nine SEER registries. The nine oldest SEER area data from
1973 to 2007 were used to calculate the age-adjusted rates for
the geographic locale, race, sex, and age at diagnosis (0–19)
Years. Rates, standard errors and 95% Conﬁdence Intervals
for the rates were calculated. The rates were per 100,000 and
age-adjusted to the 2000 US standard population. Percent
change was calculated using 1 year for each endpoint, while
the annual percent change (APC) was calculated using
weighted least squares method. The APC is the average rate
of change in a rate over several years and is used to measure
trends over time (1973–2007). Statistical signiﬁcance (mean-
ing APC was signiﬁcantly diﬀerent from zero) was assessed,
utilizing P<0.05 for APC and 95% conﬁdence interval (CI)
for rates and trends. All statistical analyses were performed
using the most recent SEER statistical package, SEER∗Stat
6.6.2.
3. Results
This result presents the study of pediatric thyroid cancer that
assessed long-term temporal trends in this malignancy. The
data comprised all pediatric thyroid carcinoma diagnosed
between 1973 and 2007. The diagnosis and the population
at risk represent 9 SEER registries with an estimated 11% of
the total US population in terms of children, 0–19 years of
age. During this period, there were 1,360 thyroid carcinomas
diagnosed,whichconsistedofallhistologicalsubtypes(papi-
llary, follicular, medullary, and anaplastic).
Table 1 demonstrates the annual incidence of pediatric
thyroid carcinoma in 1973–2007 in the SEER registries. The
incidence rate ranged from 0.4 to 0.7 per 100,000 children
of 0–19 years. The percent change was 47.9, while the APC
was signiﬁcantly diﬀerent from 0, 1.0 (95% CI: 0.5–1.6, P<
0.0001). The incidence rate was lowest in 1974, 1975, 1979,
1991, and 1997 and highest in 1976, 1992, 1998–2000, 2002,




Table 2 shows the incidence rate of pediatric thyroid can-
cer by race in 1973–2007 in the SEER registries. The inci-
dence rate for white children ranged from 0.4 to 0.8 per
100,000. Among white children, the incidence was lowest in









































































































Figure 1: Age-adjusted incidence rate and rate ratio of pediatric
thyroid carcinoma by sex, SEER dataset, in 1973–2007.
However, none of these rates were statistically signiﬁcantly
diﬀerent from the rate in 1973–2007 (P>0.05). Relative to
white children, the incidence rate was lower in blacks (Fig-
ure 2), ranging from 0.0 to 0.4 per 100000. In contrast,
severalRRsin2001–2007werestatisticallysigniﬁcantlylower
compared to 1973–2007 rates in blacks.
Table 3 illustrates the RR of pediatric thyroid cancers by
sex in the SEER registries in 1973–2007. Overall, the rate was
slightlyhigheramonggirls.Amongboys,theRRrangedfrom
0.4 to 1.8 per 100000, with the highest RR observed in 1983
(RR: 1.8, 95% CI: 0.93–3.07) and the lowest in 1994 (RR: 0.4,
95% CI: 0.08–1.18). Among girls, the RR ranged from 0.72
to 1.38 per 100,000, with the highest RR observed in 2007
(RR: 1.38, 95% CI: 1.01–1.85). Whereas in girls, the RR in
2007 was statistically signiﬁcantly diﬀerent from the rate in
1973–2007, that was not the case among boys. There were
fewer thyroid cancers diagnosed among boys (267 cases, n =
126,581,849, rate (R): 0.2 per 100,000), compared to girls (1,
093 cases, n = 121,056,935, R: 0.9 per 100,000). But overall,
there was a signiﬁcant increase in thyroid cancer in 2007
(R: 0.7 per 100,000, RR: 1.34, 95% CI: 1.01–1.75) relative to
1973–2007 (R: 0.5 per 100,000, 95% CI: 0.6–0.9). Similarly,
amonggirls,therewasasigniﬁcantincreaseinthyroidcancer
in2007 (Figure1,R:1.2per100,000, RR:1.38, 95%CI:1.01–
1.85, P = 0.04). While at any given year, the trend was higher
among girls relative to boys, there was a negative trend in
boys (PC: −19.2, nonsigniﬁcant APC: 0.4), while a positive
signiﬁcant trend was observed among girls (PC: 81.3, APC:
1.2, 95% CI: 0.6–1.8, P<0.0001).
Table 4demonstratesage-speciﬁcincidencerateforpedi-
atric thyroid carcinoma by age group at diagnosis in the
SEER registries in 1973–2007. Among children of age 0–4
years, the rate ranged from 0.0 to 0.1 with four cancers diag-
nosed between 1973 and 2007, while among the age group of
5–9 years the rate ranged from 0.0 to 0.3 per 100,000. In the
a g eg r o u po f1 0 – 1 4y e a r st h y r o i dc a r c i n o m ar a t ew a s0 . 2 –
0.9 with the rate in 2002 (R: 0.9) statistically signiﬁcantly
diﬀerent from 1973–2007. Among children in age group of4 ISRN Oncology





























































Figure 2: Age-adjusted incidence rate of pediatric thyroid carci-
noma by race, SEER dataset, in 1973–2007.
15–19 years, thyroid cancer rate ranged from 1.0 to 2.3
per 100000, with the rate in 1975 signiﬁcantly diﬀerent
from 1973–2007. There was no thyroid carcinoma diagnosed
during the ﬁrst 12 months of life (n = 12,495,777); in the
age group of 1–4 years (n = 48,601,741), there were 4 cases
of thyroid cancer (1976, 1986, 1993, and 2007), with the
rate of 0.1 per 100,000. In the age group of 5–9 years (n =
60,757,527), there were 54 tumors diagnosed, while, in the
age group of 10–14 years (n = 62,502,949), 281 carcinomas
were diagnosed, with the rate in 1992 signiﬁcantly diﬀerent
from the rate between 1973 and 2007 (rate: 0.9 per 100,000,
RR: 1.93, 95% CI: 1.06–3.23, P = 0.03). Data were insuﬃ-
cient to demonstrate trends in age group of 0–4 years, but,
among 5–9, there was a negative but insigniﬁcant trend
(PC: −62.0), while positive trends were shown among the
age groups of 10–14 years (PC: 55.0) and 15–19 years (PC:
53.4). While the APCs could not be computed for ages 5–
9 years, the APC was insigniﬁcantly higher than zero in the
age group of 10–14 years but was signiﬁcantly higher than
0 in the age group of 15–19 years (APC: 1.1, 95% CI: 0.5–
1.8, P<0.0001). Among the age group of 15–19 years (n =
63,280,790), there were 1021 tumors diagnosed, with rates
ﬂuctuating between 1.0 and 2.3 per 100,000.
Table 5 illustrates the age-adjusted incidence rate of
pediatric thyroid cancer by the 9 SEER registries in 1973–
2007. In SA the rate ranges from 0.1 to 1.3, and in
Connecticuttheratewasbetween0.1and1.3aswell,whereas
in Detroit MP, the rate was 0.2 (1980), and 0.8 in 1982 and
1983.TherewerepositivethoughinsigniﬁcanttrendsinUtah
(PC: 119.3), New Mexico (PC: 312), and Iowa (PC: 108.7,
APC 0.8), but signiﬁcant in Connecticut (PC: 312.0, APC:
2.1, P<0.0001). In contrast, nonsigniﬁcant negative trends
were observed in Detroit metropolitan (PC: −20.7), Hawaii
(PC: −16.8), and San Francisco-Oakland (PC: −47.7, APC:
0.3, P>0.05).
4. Discussion
This study was conducted to assess whether the incidence of
pediatric carcinoma has been increasing in the United States
during the past three decades. We examined the incidence
rate and trends over this period by sex, age at diagnosis, race,
and geographic locale. This investigation revealed a few rele-
vantﬁndings:ﬁrstthereisaﬂuctuatingpatternonage-adjus-
ted incidence rate in pediatric thyroid cancer based on the
nine SEER registries utilized in this study. Second, pediatric
thyroid carcinoma incidence varies by age at diagnosis, race,
and sex. Third, there is a clear pattern in the age at diagnosis,
with incidence increasing as the age increases.
Pediatric thyroid carcinoma is a rare malignancy and has
a good prognosis except the anaplastic cell type. The papil-
lary,follicular,andmedullarysubtypes,whicharecollectively
termed well-diﬀerentiated tumors, have very good prognosis
[15].Wehaveshownincreaseinthepatternofthyroidcancer
diagnosed among pediatric patients (0–19 years) in the USA
between 1973 and 2007. Despite this increase, we observed
a ﬂuctuating pattern with most increases seen in the new
millennium. Of the risk factors investigated in thyroid
cancer epidemiology, ionizing radiation remains a very well-
established ﬁnding with a perpetual consistency across study
populations and types of designs [13, 14]. The observed
increased rate of pediatric thyroid cancer in our study may
be associated with similar increase in other pediatric malig-
nancies due to the increasing use of radiation therapy in the
management of these tumors in our pediatric populations.
Relative to adults, the thyroid gland in children is most sen-
sitive to ionizing radiation, [13] which explains the increas-
ing proportion of thyroid cancer diagnosed in older children
who underwent radiation therapy for their ﬁrst primary
tumor [16]. Our study showed that the incidence rate ranged
from 0.4–0.7 per 100000 in the USA. Whereas there are no
long-term temporal trend studies to our knowledge, the lim-
ited studies done in these perspectives identiﬁed incidence
of pediatric thyroid cancer to be one in every 1000–2000
children [17].
We have also demonstrated that the incidence rate varied
by race and that white children compared to black children
had higher incidence of thyroid cancer. While the increasing
incidence trend was not signiﬁcant among white children,
the lower trends among black children were statistically
signiﬁcant between 1973–2007. The observed variability by
race in pediatric thyroid cancer remains to be explained by
examiningfactorsknowntodrivethyroidcancerthataredis-
proportionately distributed between black and white chil-
dren in the US population. Whereas this study did not assess
variability by race in the factors predisposing to thyroid can-
cer, it is plausible to expect that the observed race variabilityISRN Oncology 5
Table 1: Pediatric thyroid cancer incidence by year of diagnosis, SEER dataset, in 1973–2007.




1973 5,982,303 31 0.5 0.91 0.61 1.30
1974 6,706,606 31 0.4 0.78 0.53 1.12
1975 7,182,481 30 0.4 0.70 0.47 1.01
1976 7,094,067 51 0.7 1.21 0.90 1.61
1977 7,005,266 32 0.4 0.76 0.52 1.09
1978 6,930,226 41 0.5 0.98 0.70 1.35
1979 6,867,527 30 0.4 0.73 0.49 1.05
1980 6,825,778 33 0.4 0.81 0.55 1.15
1981 6,768,320 33 0.5 0.83 0.57 1.18
1982 6,699,252 36 0.5 0.94 0.66 1.31
1983 6,652,577 43 0.6 1.15 0.83 1.56
1984 6,604,197 31 0.5 0.84 0.57 1.20
1985 6,595,047 42 0.6 1.17 0.84 1.59
1986 6,591,444 32 0.5 0.89 0.61 1.26
1987 6,611,620 38 0.6 1.05 0.74 1.45
1988 6,654,692 29 0.4 0.82 0.55 1.19
1989 6,705,175 34 0.5 0.97 0.67 1.36
1990 6,789,031 34 0.5 0.97 0.67 1.37
1991 6,856,321 24 0.4 0.69 0.44 1.02
1992 6,945,467 45 0.7 1.27 0.92 1.71
1993 7,063,402 33 0.5 0.91 0.62 1.28
1994 7,159,479 32 0.5 0.87 0.59 1.23
1995 7,251,171 45 0.7 1.20 0.87 1.62
1996 7,344,331 35 0.5 0.91 0.63 1.27
1997 7,425,322 31 0.4 0.79 0.53 1.12
1998 7,505,219 48 0.7 1.20 0.88 1.60
1999 7,562,024 50 0.7 1.23 0.91 1.64
2000 7,597,829 51 0.7 1.25 0.93 1.66
2001 7,623,698 48 0.6 1.17 0.86 1.56
2002 7,622,505 51 0.7 1.24 0.92 1.65
2003 7,627,054 52 0.7 1.27 0.94 1.67
2004 7,650,359 44 0.6 1.06 0.77 1.44
2005 7,665,955 38 0.5 0.91 0.64 1.26
2006 7,714,191 45 0.6 1.07 0.78 1.44
2007 7,758,848 57 0.7 1.34 1.01 1.75
LL: lower limit of conﬁdence limit; UL: upper limit of conﬁdence limit; CI: conﬁdence interval; RR: rate ratio compared to 1973–2007.
in the incidence of thyroid cancer in our data may be asso-
ciated with racial variability in ﬁrst primary cancer thera-
peutics (radiation therapy), mortality from primary cancer,
secondary exposure to tobacco, diet, and parental occupa-
tion.
Thyroid cancer incidence was observed to vary by sex,
withgirlsexhibitingincreasedincidencerelativetoboys.This
observation, which supports previous data in young adult
and adult populations (14 years and older) [3, 6, 7], may be
explained in part by hormonal diﬀerences by sex. Estrogen
receptors in normal and neoplastic human thyroid tissues
had been investigated by Chaudhuri and Prinz [5]. Estrogen
may be associated with thyroid cancer since it is related
with the elevation of serum thyroxin and tri-iodothyronine6 ISRN Oncology




Rates 95% CI Rates 95% CI Rates 95% CI
LL UL LL UL LL UL
1973 0.5 0.4 0.8 0 0 0.6 0.3 0 1.5
1974 0.5 0.3 0.7 0.1 0 0.9 0 0 0.9
1975 0.4 0.2 0.6 0.2 0 0.9 0.4 0.1 1.6
1976 0.7 0.5 0.9 0.1 0 0.7 0.7 0.1 1.9
1977 0.4 0.3 0.6 0.2 0 0.9 0.6 0.1 1.9
1978 0.6 0.4 0.8 0.5 0.1 1.2 0.2 0 1.1
1979 0.4 0.3 0.6 0.2 0 0.9 0.6 0.1 1.8
1980 0.5 0.3 0.7 0.1 0 0.7 0.4 0 1.4
1981 0.4 0.3 0.6 0.3 0.1 1 0.9 0.3 2.2
1982 0.6 0.4 0.8 0.2 0 0.9 0.4 0 1.3
1983 0.7 0.5 1 0.1 0 0.7 0.5 0.1 1.6
1984 0.5 0.4 0.8 0.1 0 0.7 0.2 0 1
1985 0.7 0.5 1 0.1 0 0.7 0.4 0 1.2
1986 0.5 0.3 0.7 0.4 0.1 1 0.7 0.2 1.8
1987 0.6 0.4 0.9 0.2 0 0.8 0.5 0.1 1.5
1988 0.5 0.3 0.8 0.1 0 0.6 0.3 0 1.2
1989 0.5 0.3 0.7 0.2 0 0.8 1.1 0.4 2.3
1990 0.6 0.4 0.9 0.2 0 0.8 0.3 0 1.1
1991 0.5 0.3 0.7 0.2 0 0.8 0 0 0.5
1992 0.7 0.5 1 0.1 0 0.6 1.2 0.5 2.4
1993 0.5 0.3 0.8 0.4 0.1 1.1 0.4 0.1 1.3
1994 0.5 0.3 0.7 0.1 0 0.6 0.9 0.3 1.8
1995 0.7 0.5 1 0.2 0 0.8 0.8 0.3 1.8
1996 0.5 0.3 0.8 0.3 0.1 0.9 0.4 0.1 1.1
1997 0.4 0.3 0.7 0.1 0 0.5 0.6 0.2 1.5
1998 0.7 0.5 1 0.3 0.1 0.9 0.5 0.1 1.2
1999 0.8 0.6 1 0.2 0 0.7 0.5 0.1 1.2
2000 0.7 0.5 1 0.2 0 0.7 0.8 0.3 1.7
2001 0.8 0.5 1 0.2 0 0.6 0.2 0 0.8
2002 0.8 0.6 1.1 0.1 0 0.5 0.5 0.1 1.2
2003 0.8 0.6 1.1 0.2 0 0.6 0.7 0.3 1.5
2004 0.6 0.4 0.9 0.2 0 0.6 0.6 0.2 1.3
2005 0.5 0.4 0.8 0.1 0 0.5 0.7 0.2 1.5
2006 0.6 0.4 0.9 0.2 0 0.6 0.6 0.2 1.3
2007 0.8 0.6 1.1 0.2 0 0.6 0.8 0.3 1.6
LL: lower limit of conﬁdence limit; UL: upper limit of conﬁdence limit; CI: conﬁdence interval.
levels [18]. The fact that the variability exits in thyroid can-
cer incidence by sex due to hormonal diﬀerences is clearly
supportedbydataonageatdiagnosisofthyroidcancer.Since
this malignancy peaks during puberty, increasing in this pat-
tern until middle age [2, 7]. In addition, thyroid-stimulating
hormone (TSH) from the anterior pituitary gland may be
carcinogenic by increasing mitotic activity in the follicular
cell. Consequently, TSH elevation may be implicated in thy-
roid carcinoma carcinogenesis [19].
We found that pediatric thyroid cancer rate varied by age
at diagnosis and that the incidence was highest among chil-
dren of 15–19 years and negligible among children less than
oneyearwithnoincidencebetween1973to2007.Ferlayetal.
observedasimilarpatterninadultthyroidcancerpopulation
[20]. Incidence of thyroid cancer has been shown to be
relatively high before age 40 years, and in our data with the
pediatric population we observed highest incidence rate
among children of 15–19 years, which may be suggestive ofISRN Oncology 7




RR 95% CI RR 95% CI
LL UL LL UL
1973 1.48 0.70 2.79 0.76 0.47 1.18
1974 0.78 0.28 1.75 0.78 0.50 1.17
1975 0.84 0.33 1.78 0.67 0.42 1.01
1976 0.99 0.42 2.01 1.26 0.90 1.71
1977 1.00 0.43 2.03 0.70 0.45 1.06
1978 0.74 0.27 1.66 1.04 0.72 1.46
1979 0.93 0.37 1.95 0.67 0.43 1.02
1980 1.40 0.69 2.56 0.66 0.41 1.01
1981 0.89 0.35 1.88 0.82 0.53 1.21
1982 1.06 0.45 2.12 0.91 0.60 1.33
1983 1.76 0.93 3.07 1.00 0.67 1.44
1984 0.69 0.22 1.64 0.88 0.57 1.29
1985 1.43 0.68 2.66 1.10 0.75 1.57
1986 0.28 0.03 1.01 1.04 0.70 1.49
1987 0.69 0.22 1.64 1.14 0.78 1.61
1988 0.87 0.32 1.90 0.81 0.51 1.23
1989 0.73 0.23 1.70 1.03 0.69 1.49
1990 0.73 0.23 1.69 1.04 0.69 1.49
1991 0.57 0.15 1.46 0.72 0.44 1.11
1992 1.69 0.86 2.99 1.17 0.80 1.66
1993 0.98 0.39 2.02 0.90 0.58 1.32
1994 0.40 0.08 1.18 0.99 0.66 1.43
1995 0.54 0.15 1.38 1.37 0.98 1.87
1996 0.66 0.21 1.55 0.98 0.66 1.40
1997 0.51 0.14 1.33 0.86 0.56 1.26
1998 1.51 0.77 2.68 1.12 0.78 1.57
1999 1.24 0.59 2.32 1.24 0.88 1.70
2000 0.99 0.42 1.97 1.32 0.95 1.80
2001 1.11 0.50 2.13 1.19 0.84 1.64
2002 1.36 0.67 2.47 1.22 0.87 1.67
2003 1.35 0.66 2.44 1.25 0.89 1.71
2004 0.73 0.27 1.61 1.15 0.81 1.59
2005 1.10 0.50 2.11 0.87 0.58 1.25
2006 1.57 0.83 2.74 0.95 0.65 1.35
2007 1.19 0.57 2.23 1.38 1.01 1.85
LL: lower limit of conﬁdence limit; UL: upper limit of conﬁdence limit; CI: conﬁdence interval; RR: rate ratio.
hormonal role in thyroid carcinogenesis. Equally this impli-
cation helps to explain the sex variability in pediatric thyroid
cancer rate. The fact that we observed increasing rate from
age group of 10–19 years is also suggestive of the implication
of hormones including oral contraceptives (15–19 years) in
girls and age at onset variability in pediatric thyroid cancer
in both sexes.
Whereas the role of the environment has not been
consistently implicated in thyroid cancer carcinogenesis,
certain environment including physical environment or
geography and medical environment (diagnostics and thera-
peutics, occupation) may inﬂuence thyroid cancer incidence.
We studied temporal trend in the nine SEER registries
which began data collection in 1973 except Seattle and
Atlanta Metropolitan. While no speciﬁc patterns were
observed, registries with white pediatric population tended
to show slight increase in incidence rates. This observation
is suggestive of the role of race as a surrogate envi-
ronmental predisposing factor in pediatric thyroid malig-
nancy.8 ISRN Oncology
Table 4: Age-speciﬁc incidence of pediatric thyroid cancer in the USA, SEER dataset, in 1973–2007.
Year of
diagnosis
0–4 years 5–9 years 10–14 years 15–19 years
Population TC Rate Population TC Rate Population TC Rate Population TC Rate
1973 1,072,245 0 0 1,432,428 2 0.1 1,646,082 5 0.3 1,584,706 24 1.5
1974 1,176,199 0 0 1,579,384 0 0 1,851,090 7 0.4 1,827,895 24 1.3
1975 1,229,920 0 0 1,688,020 0 0 1,971,683 10 0.5 1,991,191 20 1.0
1976 1,188,688 1 0.1 1,686,887 3 0.2 1,913,149 12 0.6 2,006,411 35 1.7
1977 1,171,997 0 0 1,665,895 3 0.2 1,853,142 5 0.3 1,999,246 24 1.2
1978 1,187,830 0 0 1,637,991 4 0.2 1,794,352 4 0.2 1,988,727 33 1.7
1979 1,214,570 0 0 1,599,133 2 0.1 1,746,549 4 0.2 1,974,474 24 1.2
1980 1,243,643 0 0 1,564,337 2 0.1 1,723,562 4 0.2 1,946,521 27 1.4
1981 1,284,334 0 0 1,519,291 3 0.2 1,723,711 3 0.2 1,887,046 27 1.4
1982 1,308,683 0 0 1,513,782 2 0.1 1,697,129 9 0.5 1,823,596 25 1.4
1983 1,335,696 0 0 1,532,229 0 0 1,664,109 13 0.8 1,764,760 30 1.7
1984 1,352,298 0 0 1,566,143 0 0 1,618,140 5 0.3 1,721,192 26 1.5
1985 1,352,569 0 0 1,605,425 2 0.1 1,576,537 10 0.6 1,705,295 30 1.8
1986 1,357,223 1 0.1 1,644,105 1 0.1 1,524,050 7 0.5 1,710,362 23 1.3
1987 1,365,655 0 0 1,672,003 1 0.1 1,520,948 4 0.3 1,696,923 33 1.9
1988 1,376,921 0 0 1,697,507 1 0.1 1,541,516 9 0.6 1,676,400 19 1.1
1989 1,401,082 0 0 1,709,902 0 0 1,579,061 9 0.6 1,641,653 25 1.5
1990 1,430,960 0 0 1,726,047 0 0 1,631,541 3 0.2 1,612,817 31 1.9
1991 1,463,423 0 0 1,742,886 2 0.1 1,686,781 6 0.4 1,579,712 16 1
1992 1,491,441 0 0 1,752,403 1 0.1 1,731,748 15 0.9 1,589,984 29 1.8
1993 1,516,540 1 0.1 1,774,688 4 0.2 1,779,296 7 0.4 1,619,730 21 1.3
1994 1,519,630 0 0 1,808,126 2 0.1 1,800,486 8 0.4 1,663,588 22 1.3
1995 1,505,360 0 0 1,848,547 0 0 1,816,398 7 0.4 1,716,488 38 2.2
1996 1,491,423 0 0 1,888,341 0 0 1,834,425 4 0.2 1,769,159 31 1.8
1997 1,477,356 0 0 1,925,871 0 0 1,847,037 10 0.5 1,811,580 21 1.2
1998 1,473,425 0 0 1,951,753 3 0.2 1,867,304 7 0.4 1,847,826 38 2.1
1999 1,472,530 0 0 1,959,332 5 0.3 1,902,079 7 0.4 1,860,877 38 2
2000 1,471,882 0 0 1,945,304 3 0.2 1,937,644 10 0.5 1,869,474 38 2
2001 1,472,853 0 0 1,919,747 2 0.1 1,967,159 14 0.7 1,873,398 32 1.7
2002 1,489,013 0 0 1,890,526 0 0 1,984,118 12 0.6 1,873,406 39 2.1
2003 1,503,563 0 0 1,864,486 0 0 1,989,481 12 0.6 1,879,583 40 2.1
2004 1,524,279 0 0 1,850,825 2 0.1 1,982,348 11 0.6 1,898,838 31 1.6
2005 1,546,678 0 0 1,843,731 1 0.1 1,955,089 9 0.5 1,929,234 28 1.5
2006 1,556,428 0 0 1,865,235 2 0.1 1,933,272 10 0.5 1,959,038 33 1.7
2007 1,575,404 1 0.1 1,885,217 1 0.1 1,911,933 9 0.5 1,979,660 46 2.3
TC: tumor count. The population represents the pediatric population of 0–19 years in the SEER registries.
While this study represents the largest and the longest
temporal trend study in pediatric thyroid carcinoma in
North America, there are some limitations. First, the pop-
ulation studied represented an estimated 11% of the total US
population, which may render our result an underestimation
or overestimation of the incidence rate in pediatric thyroid
carcinoma. However, the observed incidence rate in general
and the incidence rate variability by sex, race, and geography
do not appear to be overly an underestimation. We could
have included other SEER registries that could have made
our data representative of an estimated 26% of the US popu-
lation. But doing so, we could have reduced the number
of years of tumor diagnosis since some of these current
registries started data collection in the late 90s and early
2000s.
In summary, this temporal trend study of pediatric thy-
roid carcinoma indicates an increase in the incidence pattern
of this malignancy given the percent change and the annual
percentchange between 1973 and 2007. In addition, the inci-
dence is higher among girls, lower among blacks, and rel-
atively higher in SEER registries with predominantly white
or Hispanic populations. Since changes in diagnostics, and
population transition, and other limitations of disease reg-
istry such as SEERS may substantially inﬂuence incidenceISRN Oncology 9





(Metropolitan) Hawaii Iowa NM Seattle (Puget Sound) Utah Atlanta
(Metropolitan)
1973 0.7 0.2 0.5 1.5 0.3 0.2 — 0.6 —
1974 0.4 0.4 0.4 0 0.1 1.2 0.7 0.6 —
1975 0.5 0.2 0.3 0.9 0.4 0.2 0.6 0.6 0.3
1976 0.5 1.1 0.6 0.6 0.8 0.6 0.4 1 0.2
1977 0.5 0.4 0.3 0.6 0.3 0.4 0.5 0.4 0.7
1978 0.4 0.6 0.5 0.3 0.9 1.2 0.6 0.2 0.2
1979 0.5 0.5 0.4 0.9 0.2 0.6 0.4 0.4 0
1980 0.6 0.4 0.2 0.6 0.5 0.4 0.3 0.7 0.5
1981 0.7 0.4 0.6 1.2 0.4 0.2 0.3 0.2 0.2
1982 0.7 0.1 0.8 0.6 0.8 0.0 0.5 0.3 0.3
1983 1 0.4 0.8 0.7 0.5 0.8 0.6 0.8 0
1984 0.4 0.4 0.6 0.3 0.8 0.4 0.2 0.6 0.2
1985 0.4 0.5 0.6 0.3 0.7 1.7 0.6 0.5 0.5
1986 0.6 0.5 0.6 0.7 0.4 0.2 0.5 0.5 0.3
1987 0.4 0.3 0.6 0.4 1 0.4 0.7 0.7 0.5
1988 0.5 0.3 0.6 0.3 0.6 0.4 0.1 0.7 0.3
1989 0.8 0.5 0.3 1 0.4 0.2 0.7 0.8 0.3
1990 0.9 0.6 0.5 0.3 0.6 1.1 0.2 0.3 0.2
1991 0.2 0.5 0.4 0.7 0.1 0.2 0.3 0.4 0.7
1992 1.3 1.1 0.6 1 0.7 0.2 0.4 0.0 0.8
1993 0.6 0.5 0.5 0.6 0.6 0.8 0.3 0.5 0.2
1994 0.8 0.2 0.6 0.6 0.2 0.2 0.6 0.1 0.8
1995 0.6 0.1 0.6 0.6 1.1 0.7 0.6 1 0.6
1996 0.6 0.6 0.5 0.9 0.6 0.4 0.4 0.4 0.4
1997 0.4 0.1 0.5 1.2 0.3 0.4 0.4 0.6 0.4
1998 0.1 0.6 0.7 0.9 0.8 0.5 0.9 0.8 0.5
1999 0.7 1.3 0.5 0.3 0.9 0.5 0.7 0.5 0.4
2000 0.8 0.9 0.6 0.6 0.6 0.7 0.8 0.8 0.3
2001 0.6 1.2 0.5 0.3 0.7 0.7 0.5 0.6 0.4
2002 0.6 0.5 0.6 0.3 0.9 0.9 0.8 0.4 1
2003 0.6 0.9 0.5 0.3 0.8 0.9 0.7 0.7 0.6
2004 0.5 0.8 0.3 0.6 0.5 1.1 0.4 0.6 0.6
2005 0.3 0.7 0.4 1.2 0.4 0.5 0.8 0.4 0.2
2006 0.8 0.8 0.6 0 0.4 0.9 0.8 0.1 0.4
2007 0.4 0.7 0.4 1.3 0.6 0.9 0.8 1.3 0.7
patterns, rates, and trends, caution is expected in the inter-
pretation of these results.
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